E-QURE Corp Signs Second Distribution Agreement in Israel

DOVER, Delaware, August 3, 2015

E-QURE Corp. (OTCQB: EQUR), a Delaware Corporate engaged in the commercialization of its Bio-electrical Signal Therapy device ("BST Device"), a new and novel electrotherapy for the noninvasive treatment of hard to heal chronic wounds, today announced that the Company has signed its second distribution agreement with Chemipal, an Israeli distributor specializing in medical devices, for the marketing and distribution of the BST device.

Chemipal is a 70 years old, sales, marketing and distribution company in Israel with annual sales exceeding $200M per annum. It is specializing in distribution of medical drugs, devices and health products to hospitals, pharmacies and clinics.

The distribution agreement was signed for a period of 10 years with annual minimum purchase obligation increasing up to $3M within 10 years. In addition to purchase obligations, the distribution agreement defines the commercial terms of the relationship. In principle, devices will be rented to hospitals and clinics at a small monthly monetary rate to cover service and repairs, while the distributor will sell disposable electrodes on "treatment days" basis. E-QURE and Chemipal will share revenue equally between them for days of treatment and device rentals. Marketing efforts will commence before yearend, once AMAR (Israel Marketing Approval) will be renewed.

Ron Weissberg, Chairman of E-QURE Corp., commented. "The Company estimates that there are about 12,000 wounds in Israel that are applicable for immediate treatment with the BST Device (stage 3 and stage 4 wounds). This present immediate market size exceeding $30M per annum, for advance wound treatment and cure. This is a small but lucrative market for us with the fundamentals necessary for success. We look forward to penetrating this additional market while progressing toward FDA approval for the BST Device here in the U.S."

About E-QURE  

E-QURE Corp (OTCQB: EQUR) develops, manufactures and markets the E-QURE BST (Bioelectrical Signal Therapy) Device for the treatment and cure chronic wounds such as; pressure ulcers; diabetics foot ulcers; venous stasis ulcers and; hard to heal ulcers. The E-QURE BST device had few regulatory approvals in different part of the world that is currently being renewed. The company is seeking FDA approval for the device to start marketing it in the US.